Sho Torii
Overview
Explore the profile of Sho Torii including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
120
Citations
1480
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening
Sato Y, Torii S, Kawai K, Yahagi K, Kutyna M, Kawakami R, et al.
Circ Cardiovasc Interv
. 2025 Feb;
18(2):e014523.
PMID: 39965045
Background: Hypoattenuated leaflet thickening (HALT) is believed to reflect leaflet thrombosis; however, no systematic histological examination of HALT has ever been performed. The aim of this study was to evaluate...
2.
Nakamura N, Shiozaki M, Torii S
Cardiovasc Diagn Ther
. 2025 Jan;
14(6):1003-1006.
PMID: 39790209
No abstract available.
3.
Nakamura N, Sakai K, Torii S, Aoki Y, Turcotte-Gosselin F, Fujinuma K, et al.
J Clin Lipidol
. 2024 Sep;
18(6):e977-e985.
PMID: 39278775
Background: Predictors of neoatherosclerosis in patients who received primary percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) remain unclear. Objective: The aim of this study is to investigate the...
4.
Aihara K, Torii S, Nakamura N, Hozumi H, Shiozaki M, Sato Y, et al.
Am Heart J
. 2024 Aug;
277:114-124.
PMID: 39121917
Background: The optimal duration of dual antiplatelet therapy after currently available drug-eluting stent (DES) implantation to prevent stent thrombosis (ST) remains controversial. Delayed healing is frequently identified as a leading...
5.
Aihara K, Torii S, Sato Y, Shiozaki M, Nakamura N, Yoshikawa A, et al.
EuroIntervention
. 2024 Aug;
20(15):e955-e956.
PMID: 39099377
No abstract available.
6.
Torii S, Yamamoto A, Yoshikawa A, Lu L, Sasaki M, Obuchi S, et al.
Cardiovasc Interv Ther
. 2024 Jul;
39(4):428-437.
PMID: 39034338
The objective of the study is to investigate the safety, feasibility, and degradation profile of a novel Mg alloy-based bioresorbable coronary scaffold (JFK-PRODUCT BRS) with thin struts (110 μm). Polymer-...
7.
Kato T, Torii S, Nakamura N, Aihara K, Terabe Y, Iida O, et al.
JACC Adv
. 2024 Jun;
2(9):100656.
PMID: 38938733
Background: The prevalence and degree of lower extremity artery disease in hemodialysis (HD) patients is higher than in the general population. However, the pathological features have not yet been evaluated....
8.
Miura Y, Koyama K, Kohno T, Soejima K, Torii S, Nakazawa G
Cardiovasc Pathol
. 2024 Apr;
71:107647.
PMID: 38649122
Background: IgG4-related disease (IgG4-RD) is a recently recognized fibro-inflammatory disorder that can affect almost any organ. IgG4-RD has also been reported in coronary arteries as periarteritis. IgG4-related coronary periarteritis may...
9.
Suemitsu K, Iida O, Torii S, Hata Y, Toyoshima T, Izumi M
J Vasc Surg Cases Innov Tech
. 2024 Mar;
10(3):101447.
PMID: 38510091
A fluoropolymer-based drug-eluting stent was implanted in an arteriovenous graft outflow venous stenosis. Two and a half years later, due to a local infection, the stent was removed surgically, and...
10.
Aihara K, Torii S, Ito M, Koseki K, Shiozaki M, Sato Y, et al.
EuroIntervention
. 2024 Mar;
20(6):e389-e398.
PMID: 38506736
Background: Drug-coated balloons (DCBs) are important treatment options for coronary artery disease; however, randomised controlled trials comparing various DCB technologies are sparse, and further investigations are needed. Aims: This preclinical...